Hikma Pharmaceuticals (HIK) Price Target Raised to GBX 1,074

Hikma Pharmaceuticals (LON:HIK) had its target price upped by Jefferies Group from GBX 1,045 ($14.06) to GBX 1,074 ($14.45) in a research note published on Monday. The brokerage currently has a hold rating on the stock.

HIK has been the topic of a number of other research reports. Barclays reduced their price target on Hikma Pharmaceuticals from GBX 2,200 ($29.61) to GBX 1,500 ($20.19) and set an overweight rating on the stock in a research note on Friday, August 25th. Stifel Nicolaus cut their target price on Hikma Pharmaceuticals from GBX 1,320 ($17.77) to GBX 1,000 ($13.46) and set a hold rating on the stock in a research report on Thursday, November 9th. Numis Securities raised Hikma Pharmaceuticals to a buy rating and set a GBX 1,300 ($17.50) price objective on the stock in a research report on Thursday, November 9th. Peel Hunt reiterated a hold rating and issued a GBX 1,390 ($18.71) price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, October 31st. Finally, Goldman Sachs Group downgraded Hikma Pharmaceuticals to a neutral rating and decreased their target price for the company from GBX 2,600 ($34.99) to GBX 1,310 ($17.63) in a research note on Tuesday, August 22nd. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of GBX 1,188.90 ($16.00).

Hikma Pharmaceuticals (HIK) traded up GBX 14.13 ($0.19) on Monday, hitting GBX 962 ($12.95). The company had a trading volume of 536,169 shares, compared to its average volume of 1,420,000. Hikma Pharmaceuticals has a 1-year low of GBX 906.50 ($12.20) and a 1-year high of GBX 2,346 ($31.57).

TRADEMARK VIOLATION WARNING: This piece was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2017/12/07/hikma-pharmaceuticals-hik-price-target-raised-to-gbx-1074.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply